author-photo

Cezary R. Swider

University of Pennsylvania

28

Papers

1089

Citations

Citation Trend

Filter By

Papers (20) Sort By

Journal Conference Others

leukemias Neuromedin U: A Myb regulated autocrine growth factor for human myeloid

2013
Show All
- Source
- Cite
- Save
Citations (1)
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice

2011 Journal of Clinical Investigation
Show All
- Source
- Cite
- Save
Citations (298)
Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma

2011 Blood
Show All
- Source
- Cite
- Save
Citations (0)
R114: Leukemic stem cells are rare and heterogeneous in human acute myelogenous leukemia

2010 Bulletin Du Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia

2009 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (87)
Effect of Obesity and Renal Insufficiency On Toxicity of High-Dose Melphalan for Multiple Myeloma.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (1)
ORIGINAL ARTICLE A robust xenotransplantation model for acute myeloid leukemia

2009
Show All
- Source
- Cite
- Save
Citations (5)
Lestaurtinib (CEP701)is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

2008 Blood
Show All
- Source
- Cite
- Save
Citations (225)
A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

2008 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (26)
A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Commentary

2008 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)